Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban

Table 5

Univariate and multivariate analysis of predictive factors for LAAT in patients treated with rivaroxaban.

Variable	Univariate analysis			Multivariate analysis
	OR	95% CI		OR	95% CI
Heart failure	4.65	1.93–11.19	0.0006	3.19	1.30–7.85	0.0116
Hypertension	2.33	0.68–8.02	0.1783
Age (per 5 years)	1.21	0.98–1.50	0.0822
Diabetes mellitus	1.98	0.75–5.23	0.1657
Stroke/TIA/peripheral thrombus	1.56	0.35–6.92	0.5603
Vascular disease	1.32	0.47–3.67	0.5953
Female	0.73	0.29–1.83	0.5
Non-paroxysmal AF	7.85	1.81–33.99	0.0058	5.73	1.29–25.58	0.0221
eGFR < 60 ml/min/1.73 m^2	1.96	0.81–4.73	0.1351

95% CI, 95% confidence interval; AF, atrial fibrillation; eGFR, estimated glomerular filtration rate; OR, odds ratio; TIA, transient ischaemic attack.